Innovative Medicines Canada welcomes the Quebec Life Sciences Strategy
Innovative Medicines Canada welcomes the life sciences strategy, the positioning of Quebec and continued work to improve access to medicines for Quebec patients.
Montreal, May 5, 2017 – Innovative Medicines Canada welcomes the Quebec Life Sciences Strategy announced jointly today by Dominique Anglade, Minister of Economy, Science and Innovation, and the Minister of Health and Social Services, Dr. Gaétan Barrette.
“We commend the Quebec Government for working in consultation with the life sciences ecosystem to develop a strategy that focuses on investment attractiveness factors. We are hopeful that the dialogue started will allow us to add more actions to those already planned in order to improve access time to medicines for Quebec patients,” said Pamela Fralick, President of Innovative Medicines Canada.
The creation of an Innovation Office within the Ministry of Health and the willingness to improve access to health data for research purposes, including real world study protocols, and the quick assessment and access to medicines are promising measures for the pharmaceutical industry. The establishment of a fund to support public and private initiatives in the life sciences sector, measures to improve Quebec’s clinical research competitiveness, and initiatives to attract more private investment and promote Quebec, are also worthy of mention.
“Balanced public finances and the commitment of Ms. Anglade and Dr. Barrette to health innovation are key factors that will contribute to the achievement of the Life Sciences Strategy goals, including positioning Quebec among the five largest North American clusters by 2027. The innovative pharmaceutical industry offers its full cooperation to achieve this objective. Our members are committed to being part of the solution to stimulate innovation, create jobs, improve patient health and increase the efficiency of the health care system,” added Frédéric Fasano, Chief Executive Officer at Servier Canada and President of the Quebec Committee for Innovative Medicines Canada.
While many international life sciences clusters are booming, it is crucial to reinforce the key attraction factor of quick market access. The orientations and actions in the strategy on the matter are encouraging. Innovative Medicines Canada would like the implementation of its recommendation to reduce Quebec drug approval delays by starting their assessment earlier for reimbursement as soon as they are approved by Health Canada, with the goal of creating a “Quebec Advantage” not only for patients, but also for the health care system and the attraction of investments.
Innovative Medicines Canada notes that the various measures taken by the Quebec Government in recent years have made it possible to control drug expenditures. The innovative pharmaceutical industry supports the government’s objective of ensuring the sustainability of the health care system and reiterates its full cooperation in maintaining a constructive dialogue to achieve this objective while ensuring that Quebecers access the best available treatments as quickly as possible. Representing barely 6% of Quebec’s health budget, spending on innovative medicines is one of the most productive investments in the health care system and creates value for the patient and the Quebec health care network.
The innovative pharmaceutical industry in Quebec:
- Recently saw its business model transformed towards research activities favouring collaborations that require increased partnerships between the external research community, the funding world and the health sector;
- Generated more than $1.4 billion in the Quebec economy in 2014; and
- Invested an average of $430 million in R & D annually in Québec over the last decade, representing nearly 40% of investments made in Canada.
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
– 30 –
For more information :